The TMB was significantly higher in the lung cancer cohort than in the brain tumor cohort across the overall populations (Figure 4A) and within the following subgroups: all MET CNV (Figure 4B), CNV2‐5 (Figure 4C), CNV 5–10 (Figure 4D), CNV ≥ 10 (Figure 4E) and MET segmental amplification (Figure 4F) (p < 0.001 for all; Wilcoxon test). The gene discussed is MET; the disease is lung carcinoma.